HDAC5 and breast cancer: Furthermore, SFN and LSD1 inhibitor combination treatment revealed superior MDA-MB-231 xenograft tumor growth inhibition by enhancing HDAC5-LSD1 axis inhibition and blocking breast cancer growth [2].